Ask AI
ProCE Banner Activity

The Newest 2-Drug Option in ART

Clinical Thought

How might the latest 2-drug ART regimen fit into the landscape of HIV treatment? Read on to learn more about the clinical trial evidence and what I think this means for clinical practice.

Released: May 12, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with American Academy of HIV Medicine, Association of Nurses in AIDS Care (ANAC), and HealthHIV

ProCE Banner

Supporters

Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.

Partners

American Academy of HIV Medicine

ProCE Banner

ANAC

ProCE Banner

HealthHIV

ProCE Banner

Target Audience

This activity is intended for physicians, pharmacists, registered nurses, and advanced practice professionals who provide HIV care in specialist or primary care settings.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Devise management strategies that integrate the recently approved doravirine/islatravir into the current landscape of ART switch options for the treatment of HIV

Disclosure

Primary Author

Chloe Orkin, MBChB, FRCP, MD: consultant/advisor/speaker: Gilead, GSK, Merck Sharp & Dohme, ViiV.